Macular Oedema in Idiopathic Macular Telangiectasia Type 1 Responsive to Aflibercept but Not Bevacizumab

  • Shibeeb O
  • Vaze A
  • Gillies M
  • et al.
N/ACitations
Citations of this article
10Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We report a patient with macular oedema due to type 1 macular telangiectasia responding to intravitreal aflibercept injection. A 51-year-old man was diagnosed with type 1 idiopathic macular telangiectasia (IMT) in the right eye. The macular oedema was refractory to initial treatment with intravitreal bevacizumab and argon laser photocoagulation. The patient was then treated with intravitreal aflibercept injections, following which the macular oedema was completely resolved and his vision was significantly improved. Intravitreal aflibercept injection appears to improve vision and reduce persistent macular oedema secondary to type 1 IMT and demonstrated promising anatomical and visual outcomes.

Cite

CITATION STYLE

APA

Shibeeb, O., Vaze, A., Gillies, M., & Gray, T. (2014). Macular Oedema in Idiopathic Macular Telangiectasia Type 1 Responsive to Aflibercept but Not Bevacizumab. Case Reports in Ophthalmological Medicine, 2014, 1–4. https://doi.org/10.1155/2014/219792

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free